The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Click ...

Neurizon Therapeutics Limited, a clinical-stage biotech company dedicated to advancing innovative treatments for ...

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results ...

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as ...

DJ Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 Sartorius Stedim Biotech SA / Key word(s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited ...

A team of researchers from the Rice Biotech Launch Pad at Rice University in Houston developed the implantable “cytokine ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...